Abstract
A robotic surgical platform known as da Vinci entered the market in 2001, mainly applied to urologic and gynaecologic surgery. This robotic approach is widely established in the urologic field in well-resourced countries, with a promising future impact {1,2}. In more recent years, robot-assisted surgery has gained interest for rectal cancer resections due to its optimal visualization and improved navigation in the narrow pelvic space. This paper, the ROLARR study, is the most important in the field so far. This international, multicenter prospective trial randomized 471 patients to either conventional laparoscopic or robotic-assisted resections. The study failed to demonstrate significant benefits of robotic surgery regarding the main outcomes of circumferential resection margin (CRM) positivity, total mesorectal excision (TME) quality, intra- and postoperative complications and 30-day mortality. However, the wide range of experience among the operating surgeons has been criticized. As with laparoscopy, it probably comes down to a matter of experience and dexterity, and no clear recommendation can be made based on the currently available evidence. See also {3-6}. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Fabian Grass and Kellie Mathis.